re: enters human insulin market in pakistan From the report The Commercialisation agreement between SciGen and PharmEvo is expected to generate in the order of over US$3 million dollars in revenue for SciGen over the three years following registration.
The agreement contains minimum order provisions. It is anticipated that registration of SciGen's insulin in Pakistan will take about 9 months. SciGen's expert Regulatory Affairs team will work with PharmEvo and the Pakistani Authorities to move registration forward as quickly as possible.
Nice report which in time will mean extra income to Siegen in time ,but I am thinking it will pull back after a brief run up
SIE Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
